Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

By sjmartinez • March 3, 2023

Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 2023 Feb 28;8(2):100884. doi: 10.1016/j.esmoop.2023.100884. Epub ahead of print. PMID: 36863095.

Tags: breast neoplasms, drug therapy combination, Gastrointestinal neoplasms, Hematology/Oncology, Publications, viral immunotherapy, virotherapy

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer

Alcantar JM, Chuang FL, Kim DD. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. Cureus. 2026 Mar 25;18(3):e105839. doi: 10.7759/cureus.105839. PMID: 42037944; PMCID: PMC13108622.

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Cho BC, Nishio M, Ahn MJ, García-Campelo R, Ponce S, Baik C, Salgia R, Kim SW, Lee JS, Yoshida T, Yu HA, Goldberg SB, Johannes[...]

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp[...]